Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

OBJECTIVES: To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets. METHODS: The BLISS trials compared belimumab 1 and 10 mg/kg versus pl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Vollenhoven, Ronald F, Petri, Michelle A, Cervera, Ricard, Roth, David A, Ji, Beulah N, Kleoudis, Christi S, Zhong, Z John, Freimuth, William
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2012
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3396451/
https://ncbi.nlm.nih.gov/pubmed/22337213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2011-200937
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados